View Future GrowthBioqual 過去の業績過去 基準チェック /06Bioqualの収益は年間平均-63.2%の割合で減少していますが、 Life Sciences業界の収益は年間 減少しています。収益は年間3.8% 5.8%割合で 減少しています。主要情報-63.21%収益成長率-63.22%EPS成長率Life Sciences 業界の成長21.51%収益成長率-5.80%株主資本利益率-3.53%ネット・マージン-2.92%前回の決算情報28 Feb 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • May 01+ 1 more updateBioqual, Inc. Announces Executive ChangesBIOQUAL, Inc. announces Dr. Mark Lewis will be retiring as President of BIOQUAL effective May 31, 2025, and is succeeded by Dr. Hanne Andersen Elyard, BIOQUAL’s Chief Science Officer. Dr. Lewis will remain as Chairman of the Board of Directors. Dr. Lewis joined BIOQUAL as Senior Scientist in August 2003. He became the Executive Vice President in October 2008 and served in that capacity until he became President and CEO in 2010. Hanne Andersen Elyard received her PhD in microbiology from the Louisiana State University Health Sciences Center in 2000. She was a postdoctoral fellow in the AIDS Vaccine Program, SAIC-Frederick, Inc. from 2001 until 2005. In January 2006 she joined BIOQUAL as a staff scientist, was promoted to Research Director in 2010, promoted to Vice President of Science in 2018 and subsequently she was promoted to Chief Scientific Officer in 2022. She has authored or co-authored more than 105 peer-reviewed scientific publications.お知らせ • Apr 25BIOQUAL Announces Retirement of Mike O'Flaherty from Board, Effective May 1, 2025BIOQUAL, Inc. announced that Mr. Michael P. O’Flaherty will retire from his role as a BIOQUAL Board Member effective May 1, 2025. Mr. O’Flaherty served as the Chief Operating Officer and Secretary of the Corporation until he retired in 2015 at which time he was elected to the BIOQUAL Board. Mr. O’Flaherty is 86 years old and has served as a Director since 2015. His retirement is not connected to any disagreements with the Board’s policies or practices.お知らせ • Jan 15BIOQUAL, Inc. Announces Changes to Board of DirectorsBIOQUAL, Inc. announced that Mr. Charles Francisco retired from his role as a BIOQUAL Board Member effective December 31, 2024. Mr. Francisco is 85 years old and has served as a director since 1992. His retirement is not connected to any disagreements with the Board’s policies or practices. Additionally, on December 31, 2024, BIOQUAL appointed Ms. Amy Johnston to the BIOQUAL Board of Directors. Ms. Johnston will replace Mr. Francisco on the Board, thus, the number of directors will not change. Ms. Johnston has been working with and managing companies in the healthcare and biotech industries for over thirty years. She holds a Bachelor of Arts in Government and English (dual degree) and a Master of Arts degree in Secondary English Education from the College of William and Mary in Virginia. Among her career accomplishments: Led cross-functional teams to build commercial biotech teams and strategies while ensuring compliance with FDA regulations, Provided critical support in pre-launch and post-launch efforts for a Hepatitis C compound, achieving $1B in sales in the first year on the commercial market, Collaborated with media and advertising agencies, managed market teams, Key Opinion Leaders, and patient advocacy groups to educate both the medical community and the patients, By revising the strategy and operating model of a design/build employee-owned utility company, Amy and her business partner increased revenue from $10 million to $25 million even during the economically unstable period of the pandemic. Amy led the team that successfully valued and negotiated the sale of her interest in the company in 2022.お知らせ • Oct 01Bioqual, Inc. Declares Dividend, Payable on October 28, 2024Bioqual, Inc.’s board of directors has declared a dividend of $0.50 per share for shareholders of record on October 7, 2024, payable on October 28, 2024.お知らせ • Sep 15Bioqual, Inc. Announces Reduction in WorkforceBIOQUAL, Inc. announced a reduction in workforce (RIF) of approximately 10% of its employees effective September 9, 2024. The RIF was a necessary cost-cutting measure due to the decrease in revenue and profitability that BIOQUAL has experienced in the last year. In a post-COVID-19 environment, the Company has seen a significant drop in the demand for their services due to the development of COVID-19 vaccines and therapeutics and needed to realign its cost structure accordingly. BIOQUAL does not expect the RIF to impact the current services it provides or to hamper its business prospects for the future.お知らせ • Oct 06Bioqual, Inc. Appoints Charles (Chris) C. Kirk, Jr., CPA as Chief Financial OfficerBIOQUAL, Inc. announced promotion of Mr. Charles (Chris) C. Kirk, Jr., CPA. to the position of chief financial officer. Mr. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both Government contracting and services-oriented companies as well as in the public accounting sector. Mr. Kirk has served as Director of Finance and Accounting for the company over the past year and has a degree in Accounting/Finance from the University of Maryland. In his role as Chief Financial Officer, Mr. Kirk will lead the Accounting/Finance team at BIOQUAL and will join the company's executive leadership team.お知らせ • Sep 28BIOQUAL Declares Dividend, Payable on October 27, 2022BIOQUAL announced that its Board of Directors has declared a dividend of $1.00 per share for shareholders of record on October 6, 2022, payable on October 27, 2022.お知らせ • May 10+ 2 more updatesBIOQUAL, Inc. Announces Retirement of Dave Newcomer as Chief Financial Officer, Effective June 3, 2022BIOQUAL, Inc. announced that Dave Newcomer will retire from his role as Chief Financial Officer effective June 3, 2022. Newcomer will remain in his current position until then to support with the transition of his responsibilities to his successor. Newcomer’s position will be filled by Charles (Chris) C. Kirk, Jr., CPA. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both government contracting and services oriented companies as well as in the public accounting sector. Kirk has served as Director of Finance and Accounting for BIOQUAL over the past year.お知らせ • Sep 22Bioqual, Inc. Announces Publication of an Investigational COVID-19 Vaccine CandidateBioqual, Inc. announced that Beth Israel Deaconess Medical Center immunologist Dan H. Barouch and colleagues, including members of the staff at BIOQUAL, showed in recently published previous work that a candidate COVID-19 vaccine raised neutralizing antibodies that robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19. In new research published September 3, 2020 in Nature Medicine, Barouch and colleagues demonstrated that the optimal vaccine elicited robust immune response in Syrian golden hamsters and prevented severe clinical disease — including weight loss, pneumonia, and death. The vaccine — developed through a collaboration between BIDMC and Janssen Pharmaceutical Companies of Johnson & Johnson — uses a common cold virus, called adenovirus serotype 26 (Ad26), to deliver the SARS-CoV-2 spike protein into host cells, where it stimulates the body to raise immune responses against the coronavirus. In the current study, the researchers immunized Syrian golden hamsters with a single injection of the Ad26-based SARS-CoV-2 vaccine, which induced neutralizing antibodies in all animals. Four weeks later, the animals were exposed to a high dose of SARS-CoV-2. Vaccinated animals lost less weight and had less virus in their lungs and other organs than unvaccinated control animals. Vaccinated animals also demonstrated lower mortality. Moreover, the researchers found that neutralizing antibody responses were inversely correlated with weight loss and viral loads in respiratory tissues. Ad26.COV2.S is currently being evaluated in clinical studies to establish the performance of the vaccine candidate in humans. In July 2020, investigators at Janssen, Beth Israel Deaconess Medical Center, and other institutions initiated a first-in-human Phase 1/2 clinical trial of the Ad26.COV2.S vaccine in healthy volunteers. Pending clinical trial out-comes, the Ad26.COV2.S vaccine is on track to start a phase 3 efficacy trial in up to 60,000 participants in September 2020.収支内訳Bioqual の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:BIOQ 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費28 Feb 2642-110030 Nov 2547011031 Aug 2547-111031 May 2549-111028 Feb 2549-211030 Nov 2450-312031 Aug 2455-112031 May 2459012029 Feb 2463112030 Nov 2362012031 Aug 2362012031 May 2363112028 Feb 2365311030 Nov 2268511031 Aug 2266510031 May 2266510028 Feb 2264510030 Nov 2160610031 Aug 2158610031 May 215869028 Feb 215559030 Nov 205458031 Aug 205158031 May 204648029 Feb 204447030 Nov 194347031 Aug 194047031 May 193937028 Feb 193834030 Nov 183634031 Aug 183744031 May 183643028 Feb 183533030 Nov 173633031 Aug 173643031 May 173743028 Feb 173743030 Nov 163743031 Aug 163643031 May 163333029 Feb 163123030 Nov 152923031 Aug 152923031 May 1529230質の高い収益: BIOQは現在利益が出ていません。利益率の向上: BIOQは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BIOQは利益が出ておらず、過去 5 年間で損失は年間63.2%の割合で増加しています。成長の加速: BIOQの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: BIOQは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 3.8% ) と比較することは困難です。株主資本利益率高いROE: BIOQは現在利益が出ていないため、自己資本利益率 ( -3.53% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 18:48終値2026/05/18 00:00収益2026/02/28年間収益2025/05/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioqual, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 01+ 1 more updateBioqual, Inc. Announces Executive ChangesBIOQUAL, Inc. announces Dr. Mark Lewis will be retiring as President of BIOQUAL effective May 31, 2025, and is succeeded by Dr. Hanne Andersen Elyard, BIOQUAL’s Chief Science Officer. Dr. Lewis will remain as Chairman of the Board of Directors. Dr. Lewis joined BIOQUAL as Senior Scientist in August 2003. He became the Executive Vice President in October 2008 and served in that capacity until he became President and CEO in 2010. Hanne Andersen Elyard received her PhD in microbiology from the Louisiana State University Health Sciences Center in 2000. She was a postdoctoral fellow in the AIDS Vaccine Program, SAIC-Frederick, Inc. from 2001 until 2005. In January 2006 she joined BIOQUAL as a staff scientist, was promoted to Research Director in 2010, promoted to Vice President of Science in 2018 and subsequently she was promoted to Chief Scientific Officer in 2022. She has authored or co-authored more than 105 peer-reviewed scientific publications.
お知らせ • Apr 25BIOQUAL Announces Retirement of Mike O'Flaherty from Board, Effective May 1, 2025BIOQUAL, Inc. announced that Mr. Michael P. O’Flaherty will retire from his role as a BIOQUAL Board Member effective May 1, 2025. Mr. O’Flaherty served as the Chief Operating Officer and Secretary of the Corporation until he retired in 2015 at which time he was elected to the BIOQUAL Board. Mr. O’Flaherty is 86 years old and has served as a Director since 2015. His retirement is not connected to any disagreements with the Board’s policies or practices.
お知らせ • Jan 15BIOQUAL, Inc. Announces Changes to Board of DirectorsBIOQUAL, Inc. announced that Mr. Charles Francisco retired from his role as a BIOQUAL Board Member effective December 31, 2024. Mr. Francisco is 85 years old and has served as a director since 1992. His retirement is not connected to any disagreements with the Board’s policies or practices. Additionally, on December 31, 2024, BIOQUAL appointed Ms. Amy Johnston to the BIOQUAL Board of Directors. Ms. Johnston will replace Mr. Francisco on the Board, thus, the number of directors will not change. Ms. Johnston has been working with and managing companies in the healthcare and biotech industries for over thirty years. She holds a Bachelor of Arts in Government and English (dual degree) and a Master of Arts degree in Secondary English Education from the College of William and Mary in Virginia. Among her career accomplishments: Led cross-functional teams to build commercial biotech teams and strategies while ensuring compliance with FDA regulations, Provided critical support in pre-launch and post-launch efforts for a Hepatitis C compound, achieving $1B in sales in the first year on the commercial market, Collaborated with media and advertising agencies, managed market teams, Key Opinion Leaders, and patient advocacy groups to educate both the medical community and the patients, By revising the strategy and operating model of a design/build employee-owned utility company, Amy and her business partner increased revenue from $10 million to $25 million even during the economically unstable period of the pandemic. Amy led the team that successfully valued and negotiated the sale of her interest in the company in 2022.
お知らせ • Oct 01Bioqual, Inc. Declares Dividend, Payable on October 28, 2024Bioqual, Inc.’s board of directors has declared a dividend of $0.50 per share for shareholders of record on October 7, 2024, payable on October 28, 2024.
お知らせ • Sep 15Bioqual, Inc. Announces Reduction in WorkforceBIOQUAL, Inc. announced a reduction in workforce (RIF) of approximately 10% of its employees effective September 9, 2024. The RIF was a necessary cost-cutting measure due to the decrease in revenue and profitability that BIOQUAL has experienced in the last year. In a post-COVID-19 environment, the Company has seen a significant drop in the demand for their services due to the development of COVID-19 vaccines and therapeutics and needed to realign its cost structure accordingly. BIOQUAL does not expect the RIF to impact the current services it provides or to hamper its business prospects for the future.
お知らせ • Oct 06Bioqual, Inc. Appoints Charles (Chris) C. Kirk, Jr., CPA as Chief Financial OfficerBIOQUAL, Inc. announced promotion of Mr. Charles (Chris) C. Kirk, Jr., CPA. to the position of chief financial officer. Mr. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both Government contracting and services-oriented companies as well as in the public accounting sector. Mr. Kirk has served as Director of Finance and Accounting for the company over the past year and has a degree in Accounting/Finance from the University of Maryland. In his role as Chief Financial Officer, Mr. Kirk will lead the Accounting/Finance team at BIOQUAL and will join the company's executive leadership team.
お知らせ • Sep 28BIOQUAL Declares Dividend, Payable on October 27, 2022BIOQUAL announced that its Board of Directors has declared a dividend of $1.00 per share for shareholders of record on October 6, 2022, payable on October 27, 2022.
お知らせ • May 10+ 2 more updatesBIOQUAL, Inc. Announces Retirement of Dave Newcomer as Chief Financial Officer, Effective June 3, 2022BIOQUAL, Inc. announced that Dave Newcomer will retire from his role as Chief Financial Officer effective June 3, 2022. Newcomer will remain in his current position until then to support with the transition of his responsibilities to his successor. Newcomer’s position will be filled by Charles (Chris) C. Kirk, Jr., CPA. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both government contracting and services oriented companies as well as in the public accounting sector. Kirk has served as Director of Finance and Accounting for BIOQUAL over the past year.
お知らせ • Sep 22Bioqual, Inc. Announces Publication of an Investigational COVID-19 Vaccine CandidateBioqual, Inc. announced that Beth Israel Deaconess Medical Center immunologist Dan H. Barouch and colleagues, including members of the staff at BIOQUAL, showed in recently published previous work that a candidate COVID-19 vaccine raised neutralizing antibodies that robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19. In new research published September 3, 2020 in Nature Medicine, Barouch and colleagues demonstrated that the optimal vaccine elicited robust immune response in Syrian golden hamsters and prevented severe clinical disease — including weight loss, pneumonia, and death. The vaccine — developed through a collaboration between BIDMC and Janssen Pharmaceutical Companies of Johnson & Johnson — uses a common cold virus, called adenovirus serotype 26 (Ad26), to deliver the SARS-CoV-2 spike protein into host cells, where it stimulates the body to raise immune responses against the coronavirus. In the current study, the researchers immunized Syrian golden hamsters with a single injection of the Ad26-based SARS-CoV-2 vaccine, which induced neutralizing antibodies in all animals. Four weeks later, the animals were exposed to a high dose of SARS-CoV-2. Vaccinated animals lost less weight and had less virus in their lungs and other organs than unvaccinated control animals. Vaccinated animals also demonstrated lower mortality. Moreover, the researchers found that neutralizing antibody responses were inversely correlated with weight loss and viral loads in respiratory tissues. Ad26.COV2.S is currently being evaluated in clinical studies to establish the performance of the vaccine candidate in humans. In July 2020, investigators at Janssen, Beth Israel Deaconess Medical Center, and other institutions initiated a first-in-human Phase 1/2 clinical trial of the Ad26.COV2.S vaccine in healthy volunteers. Pending clinical trial out-comes, the Ad26.COV2.S vaccine is on track to start a phase 3 efficacy trial in up to 60,000 participants in September 2020.